Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115299) titled 'A Randomized, Controlled, Multicenter Phase ? Trial of Sintilimab as Consolidation Therapy in Unresectable ESCC Patients Without Disease Progression After Concurrent Taxane-Based Chemoradiotherapy' on Dec. 24, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Jiangsu Cancer Hospital
Condition:
Esophagus cancer
Intervention:
Experimental group:Following completion of definitive concurrent chemoradiotherapy (CCRT), patients will receive sintilimab maintenance therapy at a dose of 200 mg administered intravenously every 3 weeks (Q3W). Treatment will be continued until: Completion ...